Vise Technologies Inc. Makes New $281,000 Investment in Amedisys, Inc. (NASDAQ:AMED)

Vise Technologies Inc. acquired a new stake in Amedisys, Inc. (NASDAQ:AMEDGet Rating) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 1,632 shares of the health services provider’s stock, valued at approximately $281,000.

Several other institutional investors and hedge funds have also made changes to their positions in AMED. Mackenzie Financial Corp boosted its holdings in shares of Amedisys by 39,235.8% in the fourth quarter. Mackenzie Financial Corp now owns 570,369 shares of the health services provider’s stock valued at $92,331,000 after acquiring an additional 568,919 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Amedisys by 23.5% during the first quarter. JPMorgan Chase & Co. now owns 1,384,041 shares of the health services provider’s stock valued at $238,457,000 after purchasing an additional 263,275 shares during the last quarter. Schroder Investment Management Group lifted its stake in Amedisys by 937.3% during the fourth quarter. Schroder Investment Management Group now owns 187,883 shares of the health services provider’s stock valued at $30,415,000 after purchasing an additional 169,770 shares during the last quarter. Frontier Capital Management Co. LLC lifted its stake in Amedisys by 98.3% during the first quarter. Frontier Capital Management Co. LLC now owns 340,741 shares of the health services provider’s stock valued at $58,706,000 after purchasing an additional 168,949 shares during the last quarter. Finally, BlackRock Inc. lifted its stake in Amedisys by 3.7% during the first quarter. BlackRock Inc. now owns 3,896,785 shares of the health services provider’s stock valued at $671,378,000 after purchasing an additional 138,484 shares during the last quarter. 93.36% of the stock is currently owned by institutional investors.

Insider Transactions at Amedisys

In related news, insider Denise M. Bohnert sold 557 shares of the firm’s stock in a transaction on Thursday, June 23rd. The shares were sold at an average price of $115.00, for a total value of $64,055.00. Following the transaction, the insider now directly owns 11,850 shares in the company, valued at approximately $1,362,750. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 2.10% of the stock is currently owned by company insiders.

Amedisys Stock Performance

Shares of AMED opened at $120.39 on Friday. The company’s fifty day moving average is $122.12 and its 200-day moving average is $130.71. Amedisys, Inc. has a 12 month low of $101.61 and a 12 month high of $188.88. The firm has a market cap of $3.91 billion, a price-to-earnings ratio of 28.06, a price-to-earnings-growth ratio of 2.89 and a beta of 0.95. The company has a quick ratio of 0.92, a current ratio of 0.92 and a debt-to-equity ratio of 0.43.

Amedisys (NASDAQ:AMEDGet Rating) last announced its quarterly earnings results on Wednesday, July 27th. The health services provider reported $1.47 EPS for the quarter, topping the consensus estimate of $1.23 by $0.24. Amedisys had a net margin of 6.33% and a return on equity of 17.81%. The company had revenue of $557.89 million for the quarter, compared to analyst estimates of $583.12 million. During the same quarter in the prior year, the business posted $1.69 EPS. Amedisys’s quarterly revenue was down 1.1% on a year-over-year basis. Equities analysts expect that Amedisys, Inc. will post 5.34 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on AMED shares. Royal Bank of Canada cut their target price on shares of Amedisys from $199.00 to $165.00 in a research note on Friday, July 29th. SVB Leerink cut their target price on shares of Amedisys from $117.00 to $107.00 and set a “market perform” rating for the company in a research note on Tuesday, June 21st. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Amedisys from $210.00 to $175.00 and set a “buy” rating for the company in a research report on Tuesday, June 21st. Cowen reduced their price target on shares of Amedisys to $125.00 in a research report on Tuesday, August 9th. Finally, Stephens reduced their price target on shares of Amedisys from $155.00 to $125.00 and set an “equal weight” rating for the company in a research report on Tuesday, June 21st. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $156.25.

About Amedisys

(Get Rating)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Further Reading

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys, Inc. (NASDAQ:AMEDGet Rating).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.